

## PUBLICATIONS

### PEER REVIEWED PAPERS

- 1) **Shapiro M**, Li LJ, Miller J. Terbinafine-induced neutropenia [Letter]. *Br J Dermatol*. 140(6):1196-7, 1999 June.
- 2) **Shapiro M**, Johnson B, Elenitsas R. Spiradenoma arising in a nevus sebaceus of Jadassohn: case report and literature review. *Am J Dermatopathol*. 21(5):462-7, 1999 Oct.
- 3) **Shapiro M**, Jimenez S, Werth VP. Pemphigus vulgaris induced by D-penicillamine therapy in a patient with systemic sclerosis. *J Am Acad Dermatol*. 42(2 Pt 1):297-9, 2000 Feb.
- 4) **Shapiro M**, Hark L, Rombeau JL. Proposed association between ileoanal j-pouch perforation and rapid consumption of a high-calorie, high-fiber meal: report of two cases. *Dis Colon Rectum*. 43(7):1008-11, 2000 Jul.
- 5) **Shapiro M**, Smith KJ, James WD, Giblin WJ, Margolis DJ, Foglia AN, McGinley F, Leyden JJ. The cutaneous microenvironment of human immunodeficiency virus (HIV)-seropositive and HIV-seronegative individuals, with special reference to staphylococcus aureus colonization. *J Clin Microbiol*. 38(9):3174-8, 2000.
- 6) **Shapiro M**, Mowad C, James WD. Contact dermatitis due to printer's ink in a milk industry employee: case report and review of the allergen paraphenylenediamine. *Am J Contact Dermatitis*. 12(2):109-112, 2001.
- 7) **Shapiro M**, Ward KM, Stern J. A near-fatal hypersensitivity reaction to abacavir: case report and literature review. *AIDS Reader* 11(4):222-6, 2001 April.
- 8) French LE, **Shapiro M**, Junkins-Hopkins JM, Vittorio CC, Rook AH. Regression of multifocal, skin-restricted, CD30-positive large T-cell lymphoma using interferon alpha and bexarotene therapy. *J Am Acad Dermatol* 2001;45:914-8.
- 9) Rook AH, Zaki MH, Wysocka M, Wood GS, Duvic M, Showe LC, Foss F, **Shapiro M**, Kuzel TM, Olsen EA, Vonderheid EC, LaLiberte R, Sherman ML. The role for interleukin-12 therapy of cutaneous T cell lymphoma. *Annals of the New York Academy of Sciences* 2001; 941:177-84.
- 10) Vittorio CC, Rook AH, French LE, **Shapiro M**, Lehrer MS, Junkins-Hopkins JM. Therapeutic advances in biological response modifiers in the treatment of cutaneous T-cell lymphoma. *BioDrugs* 2001;15(7):431-7.
- 11) McGinnis KS, **Shapiro M**, Junkins-Hopkins JM, Smith M, Lessin SR, Vittorio CC, Rook AH. Denileukin diftitox (Ontak<sup>®</sup>) for the treatment of panniculitic lymphoma. *Arch Dermatol* 2002;138(6):740-2.

- 12) Taylor AR, Vergilio J-A, **Shapiro M**, Raizen D, Hunt J, McGrath C, Rook AH, Bagg A. T-cell receptor  $\gamma$ -chain gene PCR to diagnose CNS involvement by cutaneous T-cell lymphoma. *J Mol Diagnostics* 2002;4:118-20.
- 13) **Shapiro M**, Yun M, Junkins-Hopkins JM, Vittorio CC, Schulman N, Saidman BH, Fried RG, Rook AH, Alavi A. Assessment of tumor burden and treatment response by 18F-fluorodeoxyglucose injection and positron emission tomography (FDG-PET) in patients with cutaneous T-cell and B-cell lymphomas. *J Am Acad Dermatol* 2002;47(4):623-8.
- 14) **Shapiro M**, Rook AH, Lehrer MS, Junkins-Hopkins JM, French LE, Vittorio CC. Novel multi-modality biologic response modifier therapy, including bexarotene (Targretin<sup>®</sup>) and psoralen and long-wave ultraviolet light A (PUVA), for a patient with stage IVa cutaneous T-cell lymphoma (CTCL). *J Am Acad Dermatol* 2002;47:956-61.
- 15) Vittorio CC, Junkins-Hopkins JM, McGinnis KS, **Shapiro M**, Wysocka M, Zaki MH, French LE, Rook AH. New biologic agents for the treatment of cutaneous T-cell lymphoma. *Recent Results in Cancer Research* 2002; 160:321-8.
- 16) Wysocka M, Zaki MH, French LE, Chehimi J, **Shapiro M**, Everetts SE, McGinnis KS, Montaner L, Rook AH. Sezary syndrome patients demonstrate a defect in dendritic cell populations: effects of CD40 ligand and treatment with GM-CSF on dendritic cell numbers and the production of cytokines. *Blood* 2002;100:3287-94.
- 17) French LE, Alcindor T, **Shapiro M**, Margolis DJ, Porter D, Leonard DGB, Rook AH, Foss F. Identification of amplified clonal T-cell population in the blood of patients with chronic graft versus host disease: positive correlation with response to photopheresis. *Bone Marrow Transplantation* 2002;30:509-15.
- 18) Jih DM, **Shapiro M**, James WD, Levin M, Gelfand J, Williams PT, Oakey RJ, Fakhrazadeh S, Seykora JT. Familial basaloid follicular hamartoma: lesional characterization and review of the literature. *Am J Dermatopathol* 2003;25:130-7.
- 19) McGinnis KS, **Shapiro M**, Vittorio CC, Rook AH, Junkins-Hopkins JM. Psoralen plus long-wave ultraviolet light A (PUVA) and bexarotene therapy: An effective and synergistic combined adjunct to therapy for patients with advanced cutaneous T-cell lymphoma. *Arch Dermatol* 2003;139:771-5.
- 20) Katz KA, Hivnor CM, Geist DE, **Shapiro M**, Ming ME, Werth VP. Stroke and deep venous thrombosis complicating intravenous immunoglobulin infusions. *Arch Dermatol* 2003;139:991-3.
- 21) **Shapiro M**, Wasik MA, Junkins-Hopkins JM, Rook AH, Vittorio CC, Itakura H, Frankel MC, Georgala S, Schuster SJ. Complete remission in advanced blastic NK-cell lymphoma/leukemia in elderly patients using the hyper-CVAD regimen. *Am J Hematology* 2003;74:46-51.

- 22) Richardson SK, McGinnis KS, **Shapiro M**, Lehrer MS, Kim EJ, Vittorio CC, Junkins Hopkins JM, Rook AH. Extracorporeal photopheresis and multi-modality immunomodulatory therapy in the treatment of cutaneous T-cell lymphoma. *J Cutan Med Surg* 2003 Sep 9.
- 23) French LE, **Shapiro M**, Junkins-Hopkins JM, Wolfe JT, Rook AH. Eosinophilic fasciitis and eosinophilic cellulitis in a patient with abnormal circulating clonal T cells: increased production of interleukin-5 and inhibition by interferon alfa. *J Am Acad Dermatol* 2003;49:1170-4.
- 24) Hivnor C, **Shapiro M**, Shepard J, Vittorio CC. Intravenous cidofovir for recalcitrant verruca vulgaris in the setting of HIV. *Arch Dermatol* 2004;140:13-4.
- 25) McGinnis KS, Junkins-Hopkins JM, Crawford G, **Shapiro M**, Rook AH, Vittorio CC: Low dose oral bexarotene in combination with low dose interferon alpha in the treatment of cutaneous T-cell lymphoma: Clinical synergism and possible immunologic mechanisms. *J Amer Acad Dermatol* 2004;50:375-379.
- 26) **Shapiro M**, Sosis AC, Junkins-Hopkins JM, Werth VP. Lupus erythematosus induced by medications, ultraviolet radiation, and other exogenous agents: a review, with special focus on the development of subacute cutaneous lupus in a genetically predisposed individual. *Int J Dermatol* 2004;43:87-94.
- 27) **Shapiro M**, James WD, Kessler R, Lazorik FC, Katz KA, Tam J, Nieves DS, Miller JJ. Comparison of skin biopsy triage decisions by store-and-forward teledermatology and face-to-face dermatology in 49 patients with pigmented lesions and neoplasms. *Arch Dermatol* 2004;140:525-528.
- 28) **Shapiro M**, Chren M-M, Levy RM, Elder DE, LeBoit PE, Mihm MC, Margolis DJ, Gimotty PA, Ming ME. Variability in nomenclature used for nevi with architectural Disorder and cytologic atypia (microscopically dysplastic nevi) by dermatologists and dermatopathologists. *J Cutan Pathol* 2004;31:523-30.
- 29) Seronegative secondary syphilis in two patients co-infected with human immunodeficiency virus. Kingston AA, Vujevich J, **Shapiro M**, Hivnor CM, Jukic DM, Junkins-Hopkins JM, Jih DM, Kostman JR, James WD. *Arch Dermatol* 2005;141:431-3.
- 30) Eruptive disseminated Spitz nevi. Levy RM, Ming ME, Shapiro M, Tucker M, Guerry D 4<sup>th</sup>, Cirillo-Hyland VA, Elenitsas R. *J Am Acad Dermatol* 2007.

## CHAPTERS

- 1) **Shapiro M**, Werth VP. Cutaneous infectious of the head and neck. *Facial Plast Surg Clin N Am* 2003;11:165-73.
- 2) Dermatology Secrets, pending. Chapters on Mohs surgery and Rare malignant tumors of the skin.

## LETTERS TO THE EDITOR

- 1) Rook AH, **Shapiro M**. Cutaneous squamous-cell carcinoma [Letter to the editor]. *N Engl J Med*. 345(4):296, July 26, 2001.

## ABSTRACTS

- 1) Ming ME, **Shapiro M**, Elder DE, Mihm MC, Chren MM. There is wide variation among dermatopathologists and dermatologists regarding the clinical significance and proper treatment of dysplastic nevi [abstract]. *J Cutan Pathol* 2003;30:75.
- 2) **Shapiro M**, Ming ME, Elder DE, Mihm MC, Margolis DJ, Gimotty PA, Chren MM. Investigation of the nomenclature used for microscopically dysplastic nevi [abstract]. *J Cutan Pathol* 2003;30:75-76.
- 3) **Shapiro M**, Tucker MA, Cirillo-Hyland V, Elenitsas R. Eruptive disseminated Spitz nevi [abstract]. *J Cutan Pathol* 2003;30:43-44.
- 4) Levy RM, **Shapiro M**, Ming ME. Effect of personalization and candy incentive on response rate for a mailed survey of dermatologists [abstract]. *J Invest Dermatol* 2003;121:0426.
- 5) Levy RM, **Shapiro M**, Ming ME. Effect of personalization and candy incentive on response rate for a mailed survey of dermatologists [abstract]. *J Dermatological Science* [[www.intl.elsevierhealth.com/journals/jods](http://www.intl.elsevierhealth.com/journals/jods)] 2003:0426.
- 6) **Shapiro M**, James WD, Kessler R, Lazorik FC, Tam J, Nieves DS, Katz KA, Miller JJ. Comparison of skin biopsy triage decisions by store-and-forward teledermatology and face-to-face dermatology in 49 patients with pigmented lesions and neoplasms [abstract]. *J Invest Dermatol* 2003;121:0441.
- 7) **Shapiro M**, James WD, Kessler R, Lazorik FC, Tam J, Nieves DS, Katz KA, Miller JJ. Comparison of skin biopsy triage decisions by store-and-forward teledermatology and face-to-face dermatology in 49 patients with pigmented lesions and neoplasms [abstract]. *J Dermatological Science* [[www.intl.elsevierhealth.com/journals/jods](http://www.intl.elsevierhealth.com/journals/jods)] 2003:0441.
- 8) Richardson SK, Vittorio CC, McGinnis KS, **Shapiro M**, Rook AH. High clinical response rate with multi-modality immunomodulatory therapy for Sézary syndrome [abstract]. *J Invest Dermatol* 2003;121:1209.
- 9) Richardson SK, Vittorio CC, McGinnis KS, **Shapiro M**, Rook AH. High clinical response rate with multi-modality immunomodulatory therapy for Sézary syndrome [abstract]. *J Dermatological Science* [[www.intl.elsevierhealth.com/journals/jods](http://www.intl.elsevierhealth.com/journals/jods)] 2003:1207.

## PEER REVIEWED PAPERS (IN PRESS)

- 1) Levy RM, **Shapiro M**, Cirillo-Hyland V, Tucker M, Guerry D 4<sup>th</sup>, Ming ME, Elenitsas R. Eruptive disseminated Spitz nevi.

### **PEER REVIEWED PAPERS (SUBMITTED)**

- 1) Richardson SK, Vittorio CC, McGinnis KS, **Shapiro M**, Lehrer MS, Junkins-Hopkins JM, Kim EJ, Rook AH. High Clinical Response Rate with Multi-Modality Immunomodulatory Therapy for Sézary Syndrome.

### **PEER REVIEWED PAPERS (IN PREPARATION FOR SUBMISSION)**

- 1) Ming ME, **Shapiro M**, Elder DE, Mihm MC Jr, Chren M-M. There is wide variation among dermatopathologists and dermatologists regarding the clinical significance and proper treatment of dysplastic nevi.

### **MEETINGS:**

- Shapiro M**, Elenitsas R, Roth R, Stanley J, James WD. Multiple angiomas and other cutaneous anomalies in a patient with Cowden syndrome. Gross and Microscopic Forum at 62<sup>nd</sup> Annual Meeting of the American Academy of Dermatology. 2/7/04, Washington, DC.
- Shapiro M**. Sunscreens. Pharmacy lecture series for dermatology residents at the Hospital of the University of Pennsylvania. 1/20/04.
- Shapiro M**. Syphilis: clinical presentation, diagnosis, and treatment. 10/31/03. Dermatology conference for 2<sup>nd</sup> year medical students.
- Shapiro M**. Cutaneous infections. Internal medicine noontime report. 8/21/03. Philadelphia, PA.
- Shapiro M**. Dermatology unknowns. Internal medicine noontime report. 6/19/03. Philadelphia, PA.
- Shapiro M**, James WD, Kessler R, Lazorik FC, Tam J, Nieves DS, Katz K, Miller JJ. Comparison of skin biopsy triage decisions by store-and-forward teledermatology and face-to-face dermatology in 49 patients with pigmented lesions and neoplasms. Poster presentation. 2003 Society of Investigative Dermatology meeting. 4/30-5/4/03. Miami, Florida.
- Shapiro M**, James WD, Kessler R, Lazorik FC, Tam J, Nieves DS, Katz K, Miller JJ. Comparison of skin biopsy triage decisions by store-and-forward teledermatology and face-to-face dermatology in 49 patients with pigmented lesions and neoplasms. Oral presentation at the 2003 International Dermatoepidemiology association (IDEA) meeting. 5/3/03. Miami, Florida.
- Levy RM, Shapiro M, Ming ME. Effect of personalization and candy incentive on response rate for a mailed survey of dermatologists. Poster presentation. 2003 Society of Investigative Dermatology meeting. 4/30-5/4/03. Miami, Florida.
- Richardson SK, Vittorio CC, McGinnis KS, **Shapiro M**, Rook AH. High clinical response rate with multi-modality immunomodulatory therapy for Sézary syndrome. 2003 Society of Investigative Dermatology meeting. 4/30-5/4/03. Miami, Florida.
- Shapiro M**, Tucker MA, Cirillo-Hyland V, Elenitsas R. Eruptive disseminated Spitz nevi. Philadelphia Dermatologic Society Meeting, Children's Hospital of Philadelphia. 4/25/03. Philadelphia, PA.
- Shapiro M**, Zirvi, M, Honig PJ. Hereditary acrokeratotic poikiloderma (Weary Syndrome). Gross and Microscopic Forum at 61<sup>st</sup> Annual Meeting of the American Academy of Dermatology. 3/21-3/26, 2003. San Francisco, California.
- Shapiro M**, James WD. Lichen myxedematosus/scleromyxedema. Duhring conference, University of Pennsylvania Department of Dermatology. Philadelphia Dermatologic Society Meeting, Children's Hospital of Philadelphia. 3/16/03. Philadelphia, PA.

- Shapiro M**, Tucker MA, Cirillo-Hyland V, Elenitsas R. Eruptive disseminated Spitz nevi. Oral presentation for the Duel in Dermatopathology Resident Competition. 39<sup>th</sup> Annual Meeting of the American Society of Dermatopathology. 10/10-10/13/02. Phoenix, Arizona.
- Shapiro M**, Ming ME, Elder DE, Mihm MC Jr, Margolis DJ, Gimotty A, Chren M-M. Investigation of the nomenclature used for microscopically dysplastic nevi. Oral presentation. 39<sup>th</sup> Annual Meeting of the American Society of Dermatopathology. 10/10-10/13, 2002. Phoenix, Arizona.
- Ming ME, **Shapiro M**, Elder DE, Mihm MC Jr, Chren M-M. There is wide variation among dermatopathologists and dermatologists regarding the clinical significance and proper treatment of dysplastic nevi. 39<sup>th</sup> Annual Meeting of the American Society of Dermatopathology. 10/10-10/13, 2002. Phoenix, Arizona.
- Shapiro M**, Tucker MA, Cirillo-Hyland V, Elenitsas R. Eruptive disseminated Spitz nevi. Oral presentation for Pigmented Lesion Group noontime conference. 9/25/02. Philadelphia, PA.
- Shapiro M**. The Hair Collar Sign. Philadelphia Dermatologic Society Meeting, Children's Hospital of Philadelphia. 2/02. Philadelphia, PA.
- Vergilio JA, Hunt JL, **Shapiro M**, McGrath C, Alavi J, Rook AH, Bagg A. Lymphomatous Meningitis Diagnosed by Polymerase Chain Reaction. Workshop on Genetic and Molecular Genetics in Human Hematologic Malignancies. Society for Hematopathology and the European Association for Haematopathology. 11/8-11/10/01, Boston, Massachusetts.
- Shapiro M**, Ward KM, Stern J. Hypersensitivity Reaction to Abacavir. The Danger of Rechallenging Patients. 7<sup>th</sup> Annual Thomas Bond Symposium. Pennsylvania Hospital. 6/00. Philadelphia, PA.
- Wu H, Yan A, Lyle S, Mahoney M, **Shapiro M**, Wahl J, Wheelock M, Cotsarelis G, Stanley JR. Desmoglein (Dsg) compensation hypothesis explains telogen hair loss in Dsg3 mutant mice and lack of pathology in neonatal pemphigus foliaceus (PF). Minisymposium presentation. Annual Meeting of the Society of Investigational Dermatology. 5/5-5/9, 1999. Chicago, Illinois.